Correction: MJA Practice Essentials: Infectious diseases 3: Community-acquired pneumonia
Authors: Paul DR Johnson, Lou B Irving and John D Turnidge
Published online: 5 August 2002
Re "MJA Practice Essentials – Infectious diseases 3: Community-acquired pneumonia", by Johnson PDR, Irving LB and Turnidge JD, in the 1 April issue of the Journal (Med J Aust 2002; 176: 341-347).
The authors would like to clarify an ambiguity in the text, after discussion with Professor Bart Currie (Director of Clinical Research, Tropical Medicine and International Health Unit, Menzies School of Health Research, Darwin, NT). On page 345, the last paragraph should read:
"Tropical Australia: Patients in tropical Australia, particularly those with more severe pneumonia, may be infected with B. pseudomallei (melioidosis) or A. baumannii and thus may require different initial empirical therapy. Patients with CAP in risk classes III or IV who also have risk factors for these infections (eg, diabetes, chronic airways disease, high alcohol intake or renal disease) should receive initial therapy with regimens that include intravenous gentamicin plus ceftriaxone (2 g for adults). All patients in risk class V should receive regimens that include intravenous gentamicin plus meropenem, if available. The regimen needs to be further refined if one of these pathogens is identified.26"
In addition, the last footnote to Box 6 on page 345 should be replaced with the following: "¶ In tropical Australia, melioidosis and Acinetobacter baumannii infection should be considered in all patients in risk class V and those with risk factors in risk classes III and IV."
Antibiotic recommendations are under constant review because of emerging resistance and changes in epidemiology, and we remind clinicians to refer to the latest updates of Australian antibiotic guidelines when prescribing.
Hospital-Admitted Injection-Related Infections Among Incarcerated People Who Inject Drugs in Australia: A Retrospective Cohort Study
Andrew Palmer, Matthew Carter, Jeremy Yeo, Cecilia Shim, Jason Connor, Jeremy Hayllar, Gerald Holtmann, Naomi Moy, Elliott G. Playford, Naomi Runnegar, Paul J. Clark
The Live Attenuated Influenza Vaccine in Australia: An Additional Tool for Influenza Prevention
Cyra Patel, Alexis Pillsbury, Tran Nguyen, Xia Wang, Helen E. Quinn, Clayton K. Chiu, Allen C. Cheng, Katie L. Flanagan, Zhicheng Wang
Reflex Testing for Hepatitis D Infection: A Unique Opportunity to Reduce Hepatitis D-Related Chronic Liver Disease Deaths in Australia
Jessica Howell, Lauren Andersson, Miriam T. Levy, James O'Beirne, Leon Adams, Katharine Irvine, Avik Majumdar, Golo Ahlenstiel, Kathy Jackson, Krispin Hajkowicz, Joseph Doyle, Jane Davies, Sarah Cherian, Wayne Dimech, Alexander J. Thompson
Localised Herpes Simplex Following Midline Laparotomy
Jessica S. Bulluss, Paul Chee, Matthew J. Verheyden
West Nile virus Kunjin subtype in rural NSW
Emily Gibson, Megan Whitley, Peter Murray, Linda Hueston, Jane Bennett, Raguharan Kathiresu, David N Durrheim
Differentiated and simplified oral HIV pre‐exposure prophylaxis (PrEP) models hold the key to virtually eliminating HIV transmission in Australia by 2030
Tyson Arapali, Sarah Warzywoda, Anthony K J Smith, Curtis Chan, Timothy R Broady, Erin Sullivan, Catherine MacPhail, Mohamed A Hammoud, Alexander Dowell‐Day, Benjamin R Bavinton